ID   BTK_HUMAN               Reviewed;         659 AA.
AC   Q06187; B2RAW1; Q32ML5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 217.
DE   RecName: Full=Tyrosine-protein kinase BTK;
DE            EC=2.7.10.2;
DE   AltName: Full=Agammaglobulinemia tyrosine kinase;
DE            Short=ATK;
DE   AltName: Full=B-cell progenitor kinase;
DE            Short=BPK;
DE   AltName: Full=Bruton tyrosine kinase;
GN   Name=BTK; Synonyms=AGMX1, ATK, BPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BTK-A).
RX   PubMed=8380905; DOI=10.1038/361226a0;
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RT   "The gene involved in X-linked agammaglobulinaemia is a member of the
RT   src family of protein-tyrosine kinases.";
RL   Nature 361:226-233(1993).
RN   [2]
RP   ERRATUM.
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A.,
RA   Flinter F., Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M.,
RA   Smith C.I.E., Bentley D.R.;
RL   Nature 364:362-362(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8090769; DOI=10.1073/pnas.91.19.9062;
RA   Ohta Y., Haire R.N., Litman R.T., Fu S.M., Nelson R.P., Kratz J.,
RA   Kornfeld S.J., la Morena M., Good R.A., Litman G.W.;
RT   "Genomic organization and structure of Bruton agammaglobulinemia
RT   tyrosine kinase: localization of mutations associated with varied
RT   clinical presentations and course in X chromosome-linked
RT   agammaglobulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9062-9066(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7927535; DOI=10.1007/BF01246672;
RA   Rohrer J., Parolini O., Belmont J.W., Conley M.E.;
RT   "The genomic structure of human BTK, the defective gene in X-linked
RT   agammaglobulinemia.";
RL   Immunogenetics 40:319-324(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLA SER-334; ARG-506;
RP   GLN-520; TRP-562 AND LYS-630.
RX   PubMed=7880320; DOI=10.1093/hmg/3.10.1743;
RA   Hagemann T.L., Chen Y., Rosen F.S., Kwan S.-P.;
RT   "Genomic organization of the Btk gene and exon scanning for mutations
RT   in patients with X-linked agammaglobulinemia.";
RL   Hum. Mol. Genet. 3:1743-1749(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/BF00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing
RT   the alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1-442.
RX   PubMed=8425221; DOI=10.1016/0092-8674(93)90667-F;
RA   Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C.,
RA   Klisak I., Sparkes R.S., Kubagawa H., Mohandas T., Quan S.,
RA   Belmont J.W., Cooper M.D., Conley M.E., Witte O.N.;
RT   "Deficient expression of a B cell cytoplasmic tyrosine kinase in human
RT   X-linked agammaglobulinemia.";
RL   Cell 72:279-290(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-12 AND 323-332, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 219-235, AND PHOSPHORYLATION AT TYR-223.
RX   PubMed=12573241; DOI=10.1016/S1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [13]
RP   INVOLVEMENT IN XLA-IGHD.
RX   PubMed=8013627; DOI=10.1016/0014-5793(94)00457-9;
RA   Duriez B., Duquesnoy P., Dastot F., Bougneres P., Amselem S.,
RA   Goossens M.;
RT   "An exon-skipping mutation in the btk gene of a patient with X-linked
RT   agammaglobulinemia and isolated growth hormone deficiency.";
RL   FEBS Lett. 346:165-170(1994).
RN   [14]
RP   DOMAIN PH.
RX   PubMed=8070576; DOI=10.1016/0014-5793(94)00783-7;
RA   Vihinen M., Nilsson L., Smith C.I.;
RT   "Tec homology (TH) adjacent to the PH domain.";
RL   FEBS Lett. 350:263-265(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-223 AND TYR-551, MUTAGENESIS OF TYR-223, AND
RP   ENZYME REGULATION.
RX   PubMed=8630736; DOI=10.1016/S1074-7613(00)80417-3;
RA   Park H., Wahl M.I., Afar D.E., Turck C.W., Rawlings D.J., Tam C.,
RA   Scharenberg A.M., Kinet J.P., Witte O.N.;
RT   "Regulation of Btk function by a major autophosphorylation site within
RT   the SH3 domain.";
RL   Immunity 4:515-525(1996).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, PHOSPHORYLATION AT TYR-223 AND
RP   TYR-551, AND MUTAGENESIS OF GLU-41; PRO-189; TYR-223; TRP-251; ARG-307
RP   AND TYR-551.
RX   PubMed=9012831; DOI=10.1073/pnas.94.2.604;
RA   Yang W., Desiderio S.;
RT   "BAP-135, a target for Bruton's tyrosine kinase in response to B cell
RT   receptor engagement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:604-609(1997).
RN   [17]
RP   MUTAGENESIS OF 251-TRP-TRP-252, AND INTERACTION WITH SH3BP5.
RX   PubMed=9571151; DOI=10.1006/bbrc.1998.8420;
RA   Matsushita M., Yamadori T., Kato S., Takemoto Y., Inazawa J., Baba Y.,
RA   Hashimoto S., Sekine S., Arai S., Kunikata T., Kurimoto M.,
RA   Kishimoto T., Tsukada S.;
RT   "Identification and characterization of a novel SH3-domain binding
RT   protein, Sab, which preferentially associates with Bruton's tyrosine
RT   kinase (Btk).";
RL   Biochem. Biophys. Res. Commun. 245:337-343(1998).
RN   [18]
RP   DOMAIN PH, AND SUBCELLULAR LOCATION.
RX   PubMed=10196179; DOI=10.1074/jbc.274.16.10983;
RA   Varnai P., Rother K.I., Balla T.;
RT   "Phosphatidylinositol 3-kinase-dependent membrane association of the
RT   Bruton's tyrosine kinase pleckstrin homology domain visualized in
RT   single living cells.";
RL   J. Biol. Chem. 274:10983-10989(1999).
RN   [19]
RP   INTERACTION WITH SH3BP5, AND ENZYME REGULATION.
RX   PubMed=10339589; DOI=10.1073/pnas.96.11.6341;
RA   Yamadori T., Baba Y., Mastushita M., Hashimoto S., Kurosaki M.,
RA   Kurosaki T., Kishimoto T., Tsukada S.;
RT   "Bruton's tyrosine kinase activity is negatively regulated by Sab, the
RT   Btk-SH3 domain-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6341-6346(1999).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10602036;
RX   DOI=10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0;
RA   Nore B.F., Vargas L., Mohamed A.J., Branden L.J., Backesjo C.M.,
RA   Islam T.C., Mattsson P.T., Hultenby K., Christensson B., Smith C.I.;
RT   "Redistribution of Bruton's tyrosine kinase by activation of
RT   phosphatidylinositol 3-kinase and Rho-family GTPases.";
RL   Eur. J. Immunol. 30:145-154(2000).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11016936; DOI=10.1074/jbc.M006952200;
RA   Mohamed A.J., Vargas L., Nore B.F., Backesjo C.M., Christensson B.,
RA   Smith C.I.;
RT   "Nucleocytoplasmic shuttling of Bruton's tyrosine kinase.";
RL   J. Biol. Chem. 275:40614-40619(2000).
RN   [22]
RP   PHOSPHORYLATION AT SER-180, AND ENZYME REGULATION.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG2.
RX   PubMed=11606584; DOI=10.1074/jbc.M107577200;
RA   Rodriguez R., Matsuda M., Perisic O., Bravo J., Paul A., Jones N.P.,
RA   Light Y., Swann K., Williams R.L., Katan M.;
RT   "Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme
RT   function in B-cell signaling.";
RL   J. Biol. Chem. 276:47982-47992(2001).
RN   [24]
RP   INTERACTION WITH IBTK, AND ENZYME REGULATION.
RX   PubMed=11577348; DOI=10.1038/ni1001-939;
RA   Liu W., Quinto I., Chen X., Palmieri C., Rabin R.L., Schwartz O.M.,
RA   Nelson D.L., Scala G.;
RT   "Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding
RT   protein.";
RL   Nat. Immunol. 2:939-946(2001).
RN   [25]
RP   DOMAIN, INTERACTION WITH CAV1, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=11751885; DOI=10.1074/jbc.M108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T.,
RA   Smith C.I., Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase
RT   and Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [26]
RP   PHOSPHORYLATION AT TYR-617 AND SER-623, AND MUTAGENESIS OF TYR-617.
RX   PubMed=15375214; DOI=10.1073/pnas.0405878101;
RA   Guo S., Ferl G.Z., Deora R., Riedinger M., Yin S., Kerwin J.L.,
RA   Loo J.A., Witte O.N.;
RT   "A phosphorylation site in Bruton's tyrosine kinase selectively
RT   regulates B cell calcium signaling efficiency by altering
RT   phospholipase C-gamma activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14180-14185(2004).
RN   [27]
RP   INTERACTION WITH PIN1, PHOSPHORYLATION AT SER-21 AND SER-115, AND
RP   ENZYME REGULATION.
RX   PubMed=16644721; DOI=10.1074/jbc.M603090200;
RA   Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P.,
RA   Smith C.I.;
RT   "Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase
RT   Pin1.";
RL   J. Biol. Chem. 281:18201-18207(2006).
RN   [28]
RP   FUNCTION IN THE TLR PATHWAY.
RX   PubMed=16517732; DOI=10.4049/jimmunol.176.6.3635;
RA   Horwood N.J., Page T.H., McDaid J.P., Palmer C.D., Campbell J.,
RA   Mahon T., Brennan F.M., Webster D., Foxwell B.M.;
RT   "Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF,
RT   but not IL-6, production.";
RL   J. Immunol. 176:3635-3641(2006).
RN   [29]
RP   INTERACTION WITH GTF2I AND ARID3A, AND FUNCTION.
RX   PubMed=16738337; DOI=10.1128/MCB.02009-05;
RA   Rajaiya J., Nixon J.C., Ayers N., Desgranges Z.P., Roy A.L.,
RA   Webb C.F.;
RT   "Induction of immunoglobulin heavy-chain transcription through the
RT   transcription factor Bright requires TFII-I.";
RL   Mol. Cell. Biol. 26:4758-4768(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP, AND ENZYME REGULATION.
RX   PubMed=16415872; DOI=10.1038/ni1299;
RA   Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J.,
RA   Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.J.;
RT   "Suppressor of cytokine signaling 1 negatively regulates Toll-like
RT   receptor signaling by mediating Mal degradation.";
RL   Nat. Immunol. 7:148-155(2006).
RN   [31]
RP   FUNCTION, INTERACTION WITH TLR8 AND TLR9, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-223.
RX   PubMed=17932028; DOI=10.1074/jbc.M707682200;
RA   Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A.;
RT   "Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine
RT   kinase.";
RL   J. Biol. Chem. 282:36953-36960(2007).
RN   [32]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [33]
RP   REVIEW ON FUNCTION IN REGULATION OF APOPTOSIS.
RX   PubMed=9751072; DOI=10.1016/S0006-2952(98)00122-1;
RA   Uckun F.M.;
RT   "Bruton's tyrosine kinase (BTK) as a dual-function regulator of
RT   apoptosis.";
RL   Biochem. Pharmacol. 56:683-691(1998).
RN   [34]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=19290921; DOI=10.1111/j.1600-065X.2008.00741.x;
RA   Mohamed A.J., Yu L., Backesjo C.M., Vargas L., Faryal R., Aints A.,
RA   Christensson B., Berglof A., Vihinen M., Nore B.F., Smith C.I.;
RT   "Bruton's tyrosine kinase (Btk): function, regulation, and
RT   transformation with special emphasis on the PH domain.";
RL   Immunol. Rev. 228:58-73(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-191; TYR-361 AND
RP   SER-659, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORM BTK-C).
RX   PubMed=23913792; DOI=10.1002/gcc.22091;
RA   Eifert C., Wang X., Kokabee L., Kourtidis A., Jain R., Gerdes M.J.,
RA   Conklin D.S.;
RT   "A novel isoform of the B cell tyrosine kinase BTK protects breast
RT   cancer cells from apoptosis.";
RL   Genes Chromosomes Cancer 52:961-975(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-191; TYR-223 AND
RP   SER-604, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 2-170 IN COMPLEX WITH ZINC.
RX   PubMed=9218782; DOI=10.1093/emboj/16.12.3396;
RA   Hyvoenen M., Saraste M.;
RT   "Structure of the PH domain and Btk motif from Bruton's tyrosine
RT   kinase: molecular explanations for X-linked agammaglobulinaemia.";
RL   EMBO J. 16:3396-3404(1997).
RN   [41]
RP   STRUCTURE BY NMR OF 212-275.
RX   PubMed=9485443; DOI=10.1021/bi972409f;
RA   Hansson H., Mattsson P.T., Allard P., Haapaniemi P., Vihinen M.,
RA   Smith C.I.E., Haerd T.;
RT   "Solution structure of the SH3 domain from Bruton's tyrosine kinase.";
RL   Biochemistry 37:2912-2924(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-170 IN COMPLEX WITH
RP   INOSITOL-(1,3,4,5)-TETRAKISPHOSPHATE AND ZINC, AND DOMAIN PH.
RX   PubMed=10196129; DOI=10.1016/S0969-2126(99)80057-4;
RA   Baraldi E., Carugo K.D., Hyvoenen M., Surdo P.L., Riley A.M.,
RA   Potter B.V.L., O'Brien R., Ladbury J.E., Saraste M.;
RT   "Structure of the PH domain from Bruton's tyrosine kinase in complex
RT   with inositol 1,3,4,5-tetrakisphosphate.";
RL   Structure 7:449-460(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 216-273.
RX   PubMed=10826882; DOI=10.1023/A:1008376624863;
RA   Tzeng S.R., Lou Y.C., Pai M.T., Jain M.L., Cheng J.W.;
RT   "Solution structure of the human BTK SH3 domain complexed with a
RT   proline-rich peptide from p120cbl.";
RL   J. Biomol. NMR 16:303-312(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 397-659.
RX   PubMed=11527964; DOI=10.1074/jbc.M104828200;
RA   Mao C., Zhou M., Uckun F.M.;
RT   "Crystal structure of Bruton's tyrosine kinase domain suggests a novel
RT   pathway for activation and provides insights into the molecular basis
RT   of X-linked agammaglobulinemia.";
RL   J. Biol. Chem. 276:41435-41443(2001).
RN   [45]
RP   STRUCTURE BY NMR OF 270-386.
RX   PubMed=16969585; DOI=10.1007/s10858-006-9064-3;
RA   Huang K.C., Cheng H.T., Pai M.T., Tzeng S.R., Cheng J.W.;
RT   "Solution structure and phosphopeptide binding of the SH2 domain from
RT   the human Bruton's tyrosine kinase.";
RL   J. Biomol. NMR 36:73-78(2006).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 393-656 IN COMPLEX WITH
RP   INHIBITOR.
RA   Di Paolo J.A., Huang T., Balazs M., Barbosa J., Barck K.H.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Dennis G. Jr.,
RA   Diehl L., Ferrando R.;
RT   "A novel, specific Btk inhibitor antagonizes BCR and Fc[gamma]R
RT   signaling and suppresses inflammatory arthritis.";
RL   Submitted (AUG-2010) to the PDB data bank.
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF 2-170 IN COMPLEX WITH
RP   INHIBITOR AND ZINC.
RA   Murayama K., Kato-Murayama M., Mishima C., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of PH domain of Bruton's tyrosine kinase.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 382-659 IN COMPLEX WITH
RP   INHIBITOR DASATINIB.
RX   PubMed=20052711; DOI=10.1002/pro.321;
RA   Marcotte D.J., Liu Y.T., Arduini R.M., Hession C.A., Miatkowski K.,
RA   Wildes C.P., Cullen P.F., Hong V., Hopkins B.T., Mertsching E.,
RA   Jenkins T.J., Romanowski M.J., Baker D.P., Silvian L.F.;
RT   "Structures of human Bruton's tyrosine kinase in active and inactive
RT   conformations suggest a mechanism of activation for TEC family
RT   kinases.";
RL   Protein Sci. 19:429-439(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 393-659.
RA   Di Paolo J., Huang T., Balazs M., Barbosa J., Barck K.H., Bravo B.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Diehl L.,
RA   Ferrando R., Gallion S.L., Gianetti A.M., Gribling P., Hurez V.,
RA   Hymowitz S.G., Jones R., Kropf J.E., Lee W.P., Maciejewski P.M.,
RA   Mitchell S.A., Rong H., Staker B.L., Whitney J.A., Yeh S., Young W.,
RA   Yu C., Zhang J., Reif K., Currie K.S.;
RT   "A novel, specific BTK inhibitor antagonizes BCR and FcgR signaling
RT   and suppresses inflammatory arthritis.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 387-659 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=21280133; DOI=10.1002/pro.575;
RA   Kuglstatter A., Wong A., Tsing S., Lee S.W., Lou Y., Villasenor A.G.,
RA   Bradshaw J.M., Shaw D., Barnett J.W., Browner M.F.;
RT   "Insights into the conformational flexibility of Bruton's tyrosine
RT   kinase from multiple ligand complex structures.";
RL   Protein Sci. 20:428-436(2011).
RN   [51]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=8594569; DOI=10.1093/nar/24.1.160;
RA   Vihinen M., Iwata T., Kinnon C., Kwan S.-P., Ochs H.D.,
RA   Vorechovsky I., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 24:160-165(1996).
RN   [52]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=9016530; DOI=10.1093/nar/25.1.166;
RA   Vihinen M., Belohradsky B.H., Haire R.N., Holinski-Feder E.,
RA   Kwan S.-P., Lappalainen I., Lehvaeslaiho H., Lester T., Meindl A.,
RA   Ochs H.D., Ollila J., Vorechovsky I., Weiss M., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 25:166-171(1997).
RN   [53]
RP   VARIANTS XLA TRP-288; GLY-307; ASP-607 AND
RP   SER-VAL-PHE-SER-SER-THR-ARG-103 INS.
RX   PubMed=8162056; DOI=10.1093/hmg/3.1.79;
RA   Bradley L.A.D., Sweatman A.K., Lovering R.C., Jones A.M., Morgan G.,
RA   Levinsky R.J., Kinnon C.;
RT   "Mutation detection in the X-linked agammaglobulinemia gene, BTK,
RT   using single strand conformation polymorphism analysis.";
RL   Hum. Mol. Genet. 3:79-83(1994).
RN   [54]
RP   VARIANTS XLA HIS-28 AND TRP-288.
RX   PubMed=8162018; DOI=10.1093/hmg/3.1.161;
RA   de Weers M., Mensink R.G.J., Kraakman M.E.M., Schuurman R.K.B.,
RA   Hendriks R.W.;
RT   "Mutation analysis of the Bruton's tyrosine kinase gene in X-linked
RT   agammaglobulinemia: identification of a mutation which affects the
RT   same codon as is altered in immunodeficient xid mice.";
RL   Hum. Mol. Genet. 3:161-166(1994).
RN   [55]
RP   VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND
RP   PRO-652.
RX   PubMed=7849697; DOI=10.1093/hmg/3.10.1751;
RA   Conley M.E., Fitch-Hilgenberg M.E., Cleveland J.L., Parolini O.,
RA   Rohrer J.;
RT   "Screening of genomic DNA to identify mutations in the gene for
RT   Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 3:1751-1756(1994).
RN   [56]
RP   VARIANTS XLA HIS-28; PRO-33; PRO-408; GLY-589; ASP-613 AND
RP   260-GLN--GLU-280 DEL.
RX   PubMed=7849721; DOI=10.1093/hmg/3.10.1899;
RA   Zhu Q., Zhang M., Winkelstein J., Chen S.-H., Ochs H.D.;
RT   "Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-
RT   linked agammaglobulinemia families.";
RL   Hum. Mol. Genet. 3:1899-1900(1994).
RN   [57]
RP   VARIANTS XLA GLU-430; GLN-520; GLN-525; PRO-562; VAL-582; GLY-589;
RP   GLU-594 AND ASP-613.
RX   PubMed=7809124; DOI=10.1073/pnas.91.26.12803;
RA   Vihinen M., Vetrie D., Maniar H.S., Ochs H.D., Zhu Q., Vorechovsky I.,
RA   Webster A.D.B., Notarangelo L.D., Nilsson L., Sowadski J.M.,
RA   Smith C.I.E.;
RT   "Structural basis for chromosome X-linked agammaglobulinemia: a
RT   tyrosine kinase disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12803-12807(1994).
RN   [58]
RP   VARIANT XLA PHE-64, AND CHARACTERIZATION OF OTHER XLA VARIANTS.
RX   PubMed=7849006; DOI=10.1021/bi00005a002;
RA   Vihinen M., Zvelebil J.J.M., Zhu Q., Brooimans R.A., Ochs H.D.,
RA   Zegers B.J.M., Nilsson L., Waterfield M.D., Smith C.I.E.;
RT   "Structural basis for pleckstrin homology domain mutations in X-linked
RT   agammaglobulinemia.";
RL   Biochemistry 34:1475-1481(1995).
RN   [59]
RP   VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526;
RP   TRP-562; VAL-582 AND ARG-594.
RX   PubMed=7711734; DOI=10.1093/hmg/4.1.51;
RA   Vorechovsky I., Vihinen M., de Saint Basile G., Honsova S.,
RA   Hammarstroem L., Mueller S., Nilsson L., Fischer A., Smith C.I.E.;
RT   "DNA-based mutation analysis of Bruton's tyrosine kinase gene in
RT   patients with X-linked agammaglobulinaemia.";
RL   Hum. Mol. Genet. 4:51-58(1995).
RN   [60]
RP   VARIANTS XLA LYS-567; LEU-587 AND HIS-641.
RX   PubMed=7633420; DOI=10.1093/hmg/4.4.693;
RA   Jin H., Webster A.D.B., Vihinen M., Sideras P., Vorechovsky I.,
RA   Hammarstroem L., Bernatowska-Matuszkiewicz E., Smith C.I.E.,
RA   Bobrow M., Vetrie D.;
RT   "Identification of Btk mutations in 20 unrelated patients with X-
RT   linked agammaglobulinaemia (XLA).";
RL   Hum. Mol. Genet. 4:693-700(1995).
RN   [61]
RP   VARIANTS XLA PRO-33; GLY-302 DEL; GLN-520 AND CYS-641.
RX   PubMed=7633429; DOI=10.1093/hmg/4.4.755;
RA   Gaspar H.B., Bradley L.A.D., Katz F., Lovering R.C., Roifman C.M.,
RA   Morgan G., Levinsky R.J., Kinnon C.;
RT   "Mutation analysis in Bruton's tyrosine kinase, the X-linked
RT   agammaglobulinaemia gene, including identification of an insertional
RT   hotspot.";
RL   Hum. Mol. Genet. 4:755-757(1995).
RN   [62]
RP   VARIANTS XLA ASN-429 AND ARG-477.
RX   PubMed=8634718; DOI=10.1093/hmg/4.12.2403;
RA   Vorechovsky I., Luo L., de Saint Basile G., Hammarstroem L.,
RA   Webster A.D.B., Smith C.I.E.;
RT   "Improved oligonucleotide primer set for molecular diagnosis of X-
RT   linked agammaglobulinaemia: predominance of amino acid substitutions
RT   in the catalytic domain of Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 4:2403-2405(1995).
RN   [63]
RP   VARIANTS XLA GLU-302 AND ASP-476.
RX   PubMed=7627183; DOI=10.1002/humu.1380050405;
RA   Hagemann T.L., Rosen F.S., Kwan S.-P.;
RT   "Characterization of germline mutations of the gene encoding Bruton's
RT   tyrosine kinase in families with X-linked agammaglobulinemia.";
RL   Hum. Mutat. 5:296-302(1995).
RN   [64]
RP   VARIANT XLA PHE-358.
RX   PubMed=7897635; DOI=10.1136/jmg.32.1.77;
RA   Ohashi Y., Tsuchiya S., Konno T.;
RT   "A new point mutation involving a highly conserved leucine in the Btk
RT   SH2 domain in a family with X linked agammaglobulinaemia.";
RL   J. Med. Genet. 32:77-79(1995).
RN   [65]
RP   VARIANT XLA PRO-295.
RX   PubMed=8723128;
RX   DOI=10.1002/(SICI)1096-8628(19960503)63:1<318::AID-AJMG53>3.0.CO;2-N;
RA   Schuster V., Seidenspinner S., Kreth H.W.;
RT   "Detection of a novel mutation in the SRC homology domain 2 (SH2) of
RT   Bruton's tyrosine kinase and direct female carrier evaluation in a
RT   family with X-linked agammaglobulinemia.";
RL   Am. J. Med. Genet. 63:318-322(1996).
RN   [66]
RP   VARIANTS XLA ARG-12; PRO-28; GLU-302; TRP-502; HIS-521; TYR-633 AND
RP   SER-644.
RX   PubMed=8695804;
RA   Hashimoto S., Tsukada S., Matsushita M., Miyawaki T., Niida Y.,
RA   Yachie A., Kobayashi S., Iwata T., Hayakawa H., Matsuoka H., Tsuge I.,
RA   Yamadori T., Kunikata T., Arai S., Yoshizaki K., Taniguchi N.,
RA   Kishimoto T.;
RT   "Identification of Bruton's tyrosine kinase (Btk) gene mutations and
RT   characterization of the derived proteins in 35 X-linked
RT   agammaglobulinemia families: a nationwide study of Btk deficiency in
RT   Japan.";
RL   Blood 88:561-573(1996).
RN   [67]
RP   VARIANTS XLA TRP-288; LYS-544 AND PRO-592.
RX   PubMed=8834236; DOI=10.1007/BF02267060;
RA   Kobayashi S., Iwata T., Saito M., Iwasaki R., Matsumoto H.,
RA   Naritaka S., Kono Y., Hayashi Y.;
RT   "Mutations of the Btk gene in 12 unrelated families with X-linked
RT   agammaglobulinemia in Japan.";
RL   Hum. Genet. 97:424-430(1996).
RN   [68]
RP   VARIANTS XLA SER-154 AND ARG-155.
RX   PubMed=9280283; DOI=10.1016/S0014-5793(97)00912-5;
RA   Vihinen M., Nore B., Mattsson P.T., Backesj C.-M., Nars M.,
RA   Koutaniemi S., Watanabe C., Lester T., Jones A.M., Ochs H.D.,
RA   Smith C.I.E.;
RT   "Missense mutations affecting a conserved cysteine pair in the TH
RT   domain of Btk.";
RL   FEBS Lett. 413:205-210(1997).
RN   [69]
RP   VARIANTS XLA.
RX   PubMed=9260159;
RA   Saha B.K., Curtis S.K., Vogler L.B., Vihinen M.;
RT   "Molecular and structural characterization of five novel mutations in
RT   the Bruton's tyrosine kinase gene from patients with X-linked
RT   agammaglobulinemia.";
RL   Mol. Med. 3:477-485(1997).
RN   [70]
RP   VARIANTS XLA GLN-288; THR-307; ARG-430; ASP-445; GLY-525; PHE-535;
RP   LEU-563 AND PRO-622.
RX   PubMed=9545398; DOI=10.1086/301828;
RA   Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J.;
RT   "Mutations in btk in patients with presumed X-linked
RT   agammaglobulinemia.";
RL   Am. J. Hum. Genet. 62:1034-1043(1998).
RN   [71]
RP   VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155;
RP   PRO-295; PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525;
RP   SER-559; TRP-562; GLU-594; THR-619; GLY-626 AND HIS-641.
RX   PubMed=9445504; DOI=10.1542/peds.101.2.276;
RA   Holinski-Feder E., Weiss M., Brandau O., Jedele K.B., Nore B.,
RA   Baeckesjoe C.-M., Vihinen M., Hubbard S.R., Belohradsky B.H.,
RA   Smith C.I.E., Meindl A.;
RT   "Mutation screening of the BTK gene in 56 families with X-linked
RT   agammaglobulinemia (XLA): 47 unique mutations without correlation to
RT   clinical course.";
RL   Pediatrics 101:276-284(1998).
RN   [72]
RP   VARIANTS XLA.
RX   PubMed=10220140;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L;
RA   Vihinen M., Kwan S.-P., Lester T., Ochs H.D., Resnick I., Vaeliaho J.,
RA   Conley M.E., Smith C.I.E.;
RT   "Mutations of the human BTK gene coding for Bruton tyrosine kinase in
RT   X-linked agammaglobulinemia.";
RL   Hum. Mutat. 13:280-285(1999).
RN   [73]
RP   VARIANT XLA PRO-562.
RX   PubMed=10678660;
RX   DOI=10.1002/(SICI)1096-8628(20000131)90:3<229::AID-AJMG8>3.0.CO;2-Q;
RA   Curtis S.K., Hebert M.D., Saha B.K.;
RT   "Twin carriers of X-linked agammaglobulinemia (XLA) due to germline
RT   mutation in the Btk gene.";
RL   Am. J. Med. Genet. 90:229-232(2000).
RN   [74]
RP   VARIANTS XLA SER-39; PRO-512; GLN-512; GLY-544; TYR-578 AND LYS-589.
RX   PubMed=10612838;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<117::AID-HUMU26>3.0.CO;2-H;
RA   Orlandi P., Ritis K., Moschese V., Angelini F., Arvanitidis K.,
RA   Speletas M., Sideras P., Plebani A., Rossi P.;
RT   "Identification of nine novel mutations in the Bruton's tyrosine
RT   kinase gene in X-linked agammaglobulinaemia patients.";
RL   Hum. Mutat. 15:117-117(2000).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-82 AND LYS-190.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [76]
RP   VARIANT SER-481, AND CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869598; DOI=10.1056/NEJMoa1400029;
RA   Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M.,
RA   Ruppert A.S., Xue L., Li D.H., Steggerda S.M., Versele M., Dave S.S.,
RA   Zhang J., Yilmaz A.S., Jaglowski S.M., Blum K.A., Lozanski A.,
RA   Lozanski G., James D.F., Barrientos J.C., Lichter P., Stilgenbauer S.,
RA   Buggy J.J., Chang B.Y., Johnson A.J., Byrd J.C.;
RT   "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor
RT   ibrutinib.";
RL   N. Engl. J. Med. 370:2286-2294(2014).
RN   [77]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869597; DOI=10.1056/NEJMc1402716;
RA   Furman R.R., Cheng S., Lu P., Setty M., Perez A.R., Perez A.R.,
RA   Guo A., Racchumi J., Xu G., Wu H., Ma J., Steggerda S.M., Coleman M.,
RA   Leslie C., Wang Y.L.;
RT   "Ibrutinib resistance in chronic lymphocytic leukemia.";
RL   N. Engl. J. Med. 370:2352-2354(2014).
RN   [78]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=25189416; DOI=10.1038/leu.2014.263;
RA   Cheng S., Guo A., Lu P., Ma J., Coleman M., Wang Y.L.;
RT   "Functional characterization of BTK(C481S) mutation that confers
RT   ibrutinib resistance: exploration of alternative kinase inhibitors.";
RL   Leukemia 29:895-900(2015).
CC   -!- FUNCTION: Non-receptor tyrosine kinase indispensable for B
CC       lymphocyte development, differentiation and signaling. Binding of
CC       antigen to the B-cell antigen receptor (BCR) triggers signaling
CC       that ultimately leads to B-cell activation. After BCR engagement
CC       and activation at the plasma membrane, phosphorylates PLCG2 at
CC       several sites, igniting the downstream signaling pathway through
CC       calcium mobilization, followed by activation of the protein kinase
CC       C (PKC) family members. PLCG2 phosphorylation is performed in
CC       close cooperation with the adapter protein B-cell linker protein
CC       BLNK. BTK acts as a platform to bring together a diverse array of
CC       signaling proteins and is implicated in cytokine receptor
CC       signaling pathways. Plays an important role in the function of
CC       immune cells of innate as well as adaptive immunity, as a
CC       component of the Toll-like receptors (TLR) pathway. The TLR
CC       pathway acts as a primary surveillance system for the detection of
CC       pathogens and are crucial to the activation of host defense.
CC       Especially, is a critical molecule in regulating TLR9 activation
CC       in splenic B-cells. Within the TLR pathway, induces tyrosine
CC       phosphorylation of TIRAP which leads to TIRAP degradation. BTK
CC       plays also a critical role in transcription regulation. Induces
CC       the activity of NF-kappa-B, which is involved in regulating the
CC       expression of hundreds of genes. BTK is involved on the signaling
CC       pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently
CC       phosphorylates transcription factor GTF2I on tyrosine residues in
CC       response to BCR. GTF2I then translocates to the nucleus to bind
CC       regulatory enhancer elements to modulate gene expression. ARID3A
CC       and NFAT are other transcriptional target of BTK. BTK is required
CC       for the formation of functional ARID3A DNA-binding complexes.
CC       There is however no evidence that BTK itself binds directly to
CC       DNA. BTK has a dual role in the regulation of apoptosis.
CC       {ECO:0000269|PubMed:11606584, ECO:0000269|PubMed:16415872,
CC       ECO:0000269|PubMed:16517732, ECO:0000269|PubMed:16738337,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:9012831}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- ENZYME REGULATION: Activated by phosphorylation. In primary B
CC       lymphocytes, is almost always non-phosphorylated and is thus
CC       catalytically inactive. Stimulation of TLR8 and TLR9 causes BTK
CC       activation. As a negative feedback mechanism to fine-tune BCR
CC       signaling, activated PRKCB down-modulates BTK function via direct
CC       phosphorylation of BTK at Ser-180, resulting in translocation of
CC       BTK back to the cytoplasmic fraction. PIN1, SH3BP5, and IBTK were
CC       also identified as BTK activity inhibitors. Interaction with CAV1
CC       leads to dramatic down-regulation of the kinase activity of BTK.
CC       LFM-13A is a specific inhibitor of BTK. Dasatinib, a cancer drug
CC       acting as a tyrosine kinase inhibitor, also blocks BTK activity.
CC       {ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736}.
CC   -!- SUBUNIT: Binds GTF2I through the PH domain. Interacts with SH3BP5
CC       via the SH3 domain. Interacts with IBTK via its PH domain.
CC       Interacts with ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9.
CC       {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10339589,
CC       ECO:0000269|PubMed:11577348, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:16738337,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20052711, ECO:0000269|PubMed:21280133,
CC       ECO:0000269|PubMed:9218782, ECO:0000269|PubMed:9571151,
CC       ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-624835, EBI-624835;
CC       Q99856:ARID3A; NbExp=3; IntAct=EBI-624835, EBI-5458244;
CC       Q8WV28:BLNK; NbExp=2; IntAct=EBI-624835, EBI-2623522;
CC       P78347:GTF2I; NbExp=6; IntAct=EBI-624835, EBI-359622;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-624835, EBI-352572;
CC       P21145:MAL; NbExp=5; IntAct=EBI-624835, EBI-3932027;
CC       A4D127:MEOX2; NbExp=3; IntAct=EBI-624835, EBI-10172134;
CC       Q04759:PRKCQ; NbExp=2; IntAct=EBI-624835, EBI-374762;
CC       O60239:SH3BP5; NbExp=4; IntAct=EBI-624835, EBI-624860;
CC       P42768:WAS; NbExp=4; IntAct=EBI-624835, EBI-346375;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral
CC       membrane protein. Nucleus. Note=In steady state, BTK is
CC       predominantly cytosolic. Following B-cell receptor (BCR)
CC       engagement by antigen, translocates to the plasma membrane through
CC       its PH domain. Plasma membrane localization is a critical step in
CC       the activation of BTK. A fraction of BTK also shuttles between the
CC       nucleus and the cytoplasm, and nuclear export is mediated by the
CC       nuclear export receptor CRM1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=BTK-A;
CC         IsoId=Q06187-1; Sequence=Displayed;
CC       Name=BTK-C;
CC         IsoId=Q06187-2; Sequence=VSP_053838;
CC         Note=Produced by alternative promoter usage. Predominant form in
CC         many tumor cells where it may function as an anti-apoptotic cell
CC         survival factor.;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in B-lymphocytes.
CC   -!- DOMAIN: The PH domain mediates the binding to inositol
CC       polyphosphate and phosphoinositides, leading to its targeting to
CC       the plasma membrane. It is extended in the BTK kinase family by a
CC       region designated the TH (Tec homology) domain, which consists of
CC       about 80 residues preceding the SH3 domain.
CC       {ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:10196179,
CC       ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:8070576}.
CC   -!- PTM: Following B-cell receptor (BCR) engagement, translocates to
CC       the plasma membrane where it gets phosphorylated at Tyr-551 by LYN
CC       and SYK. Phosphorylation at Tyr-551 is followed by
CC       autophosphorylation of Tyr-223 which may create a docking site for
CC       a SH2 containing protein. Phosphorylation at Ser-180 by PRKCB,
CC       leads in translocation of BTK back to the cytoplasmic fraction.
CC       Phosphorylation at Ser-21 and Ser-115 creates a binding site for
CC       PIN1 at these Ser-Pro motifs, and promotes it's recruitment.
CC       {ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:12573241,
CC       ECO:0000269|PubMed:15375214, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736,
CC       ECO:0000269|PubMed:9012831}.
CC   -!- DISEASE: X-linked agammaglobulinemia (XLA) [MIM:300755]: Humoral
CC       immunodeficiency disease which results in developmental defects in
CC       the maturation pathway of B-cells. Affected boys have normal
CC       levels of pre-B-cells in their bone marrow but virtually no
CC       circulating mature B-lymphocytes. This results in a lack of
CC       immunoglobulins of all classes and leads to recurrent bacterial
CC       infections like otitis, conjunctivitis, dermatitis, sinusitis in
CC       the first few years of life, or even some patients present
CC       overwhelming sepsis or meningitis, resulting in death in a few
CC       hours. Treatment in most cases is by infusion of intravenous
CC       immunoglobulin. {ECO:0000269|PubMed:10220140,
CC       ECO:0000269|PubMed:10612838, ECO:0000269|PubMed:10678660,
CC       ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:7633420,
CC       ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7711734,
CC       ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849006,
CC       ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7849721,
CC       ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:7897635,
CC       ECO:0000269|PubMed:8013627, ECO:0000269|PubMed:8162018,
CC       ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8594569,
CC       ECO:0000269|PubMed:8634718, ECO:0000269|PubMed:8695804,
CC       ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:8834236,
CC       ECO:0000269|PubMed:9016530, ECO:0000269|PubMed:9260159,
CC       ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504,
CC       ECO:0000269|PubMed:9545398}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: X-linked hypogammaglobulinemia and isolated growth
CC       hormone deficiency (XLA-IGHD) [MIM:307200]: In rare cases XLA is
CC       inherited together with isolated growth hormone deficiency (IGHD).
CC       {ECO:0000269|PubMed:8013627}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BTKID851chXq22.html";
CC   -!- WEB RESOURCE: Name=BTKbase; Note=BTK mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/BTKbase/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58957; CAA41728.1; -; mRNA.
DR   EMBL; U10087; AAB60639.1; -; Genomic_DNA.
DR   EMBL; U10084; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10085; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10086; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; L31572; AAA61479.1; -; Genomic_DNA.
DR   EMBL; L31557; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31558; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31559; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31561; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31563; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31564; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31565; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31566; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31567; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31568; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31569; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31570; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31571; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; U13433; AAC51347.1; -; Genomic_DNA.
DR   EMBL; U13410; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13412; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13413; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13414; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13415; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13416; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13417; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13422; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13423; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13424; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13425; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13427; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13428; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13429; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13430; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13431; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13432; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U78027; AAB64205.1; -; Genomic_DNA.
DR   EMBL; AK314382; BAG37008.1; -; mRNA.
DR   EMBL; AL035422; CAB55876.1; -; Genomic_DNA.
DR   EMBL; BC109079; AAI09080.1; -; mRNA.
DR   EMBL; BC109080; AAI09081.1; -; mRNA.
DR   CCDS; CCDS14482.1; -. [Q06187-1]
DR   CCDS; CCDS76003.1; -. [Q06187-2]
DR   PIR; I37212; A45184.
DR   RefSeq; NP_000052.1; NM_000061.2. [Q06187-1]
DR   RefSeq; NP_001274273.1; NM_001287344.1. [Q06187-2]
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   UniGene; Hs.159494; -.
DR   UniGene; Hs.733206; -.
DR   PDB; 1AWW; NMR; -; A=212-275.
DR   PDB; 1AWX; NMR; -; A=212-275.
DR   PDB; 1B55; X-ray; 2.40 A; A/B=2-170.
DR   PDB; 1BTK; X-ray; 1.60 A; A/B=2-170.
DR   PDB; 1BWN; X-ray; 2.10 A; A/B=2-170.
DR   PDB; 1K2P; X-ray; 2.10 A; A/B=397-659.
DR   PDB; 1QLY; NMR; -; A=216-273.
DR   PDB; 2GE9; NMR; -; A=270-387.
DR   PDB; 2Z0P; X-ray; 2.58 A; A/B/C/D=2-170.
DR   PDB; 3GEN; X-ray; 1.60 A; A=382-659.
DR   PDB; 3K54; X-ray; 1.94 A; A=382-659.
DR   PDB; 3OCS; X-ray; 1.80 A; A=393-656.
DR   PDB; 3OCT; X-ray; 1.95 A; A=393-656.
DR   PDB; 3P08; X-ray; 2.30 A; A/B=393-659.
DR   PDB; 3PIX; X-ray; 1.85 A; A=387-659.
DR   PDB; 3PIY; X-ray; 2.55 A; A=387-659.
DR   PDB; 3PIZ; X-ray; 2.21 A; A=387-659.
DR   PDB; 3PJ1; X-ray; 2.00 A; A=387-659.
DR   PDB; 3PJ2; X-ray; 1.75 A; A=387-659.
DR   PDB; 3PJ3; X-ray; 1.85 A; A=387-659.
DR   PDB; 4NWM; X-ray; 2.03 A; A/B=396-657.
DR   PDB; 4OT5; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OT6; X-ray; 2.05 A; A=378-659.
DR   PDB; 4OTF; X-ray; 1.95 A; A=393-657.
DR   PDB; 4OTQ; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OTR; X-ray; 1.95 A; A=378-659.
DR   PDB; 4RFY; X-ray; 1.70 A; A=378-659.
DR   PDB; 4RFZ; X-ray; 1.17 A; A=378-659.
DR   PDB; 4RG0; X-ray; 2.50 A; A=378-659.
DR   PDB; 4RX5; X-ray; 1.36 A; A=393-657.
DR   PDB; 4YHF; X-ray; 2.20 A; A/B=382-659.
DR   PDB; 4Z3V; X-ray; 1.60 A; A=382-659.
DR   PDB; 4ZLY; X-ray; 1.65 A; A=389-658.
DR   PDB; 4ZLZ; X-ray; 2.00 A; A=389-658.
DR   PDB; 5BPY; X-ray; 2.31 A; A/B=396-659.
DR   PDB; 5BQ0; X-ray; 1.57 A; A=382-659.
DR   PDB; 5FBN; X-ray; 1.80 A; C/D=389-659.
DR   PDB; 5FBO; X-ray; 1.89 A; A=389-659.
DR   PDB; 5JRS; X-ray; 1.97 A; A/B=396-659.
DR   PDB; 5KUP; X-ray; 1.39 A; A=393-657.
DR   PDB; 5T18; X-ray; 1.50 A; A=396-659.
DR   PDB; 5U9D; X-ray; 1.33 A; A=389-659.
DR   PDBsum; 1AWW; -.
DR   PDBsum; 1AWX; -.
DR   PDBsum; 1B55; -.
DR   PDBsum; 1BTK; -.
DR   PDBsum; 1BWN; -.
DR   PDBsum; 1K2P; -.
DR   PDBsum; 1QLY; -.
DR   PDBsum; 2GE9; -.
DR   PDBsum; 2Z0P; -.
DR   PDBsum; 3GEN; -.
DR   PDBsum; 3K54; -.
DR   PDBsum; 3OCS; -.
DR   PDBsum; 3OCT; -.
DR   PDBsum; 3P08; -.
DR   PDBsum; 3PIX; -.
DR   PDBsum; 3PIY; -.
DR   PDBsum; 3PIZ; -.
DR   PDBsum; 3PJ1; -.
DR   PDBsum; 3PJ2; -.
DR   PDBsum; 3PJ3; -.
DR   PDBsum; 4NWM; -.
DR   PDBsum; 4OT5; -.
DR   PDBsum; 4OT6; -.
DR   PDBsum; 4OTF; -.
DR   PDBsum; 4OTQ; -.
DR   PDBsum; 4OTR; -.
DR   PDBsum; 4RFY; -.
DR   PDBsum; 4RFZ; -.
DR   PDBsum; 4RG0; -.
DR   PDBsum; 4RX5; -.
DR   PDBsum; 4YHF; -.
DR   PDBsum; 4Z3V; -.
DR   PDBsum; 4ZLY; -.
DR   PDBsum; 4ZLZ; -.
DR   PDBsum; 5BPY; -.
DR   PDBsum; 5BQ0; -.
DR   PDBsum; 5FBN; -.
DR   PDBsum; 5FBO; -.
DR   PDBsum; 5JRS; -.
DR   PDBsum; 5KUP; -.
DR   PDBsum; 5T18; -.
DR   PDBsum; 5U9D; -.
DR   ProteinModelPortal; Q06187; -.
DR   SMR; Q06187; -.
DR   BioGrid; 107160; 79.
DR   DIP; DIP-34071N; -.
DR   IntAct; Q06187; 49.
DR   MINT; MINT-110243; -.
DR   STRING; 9606.ENSP00000308176; -.
DR   BindingDB; Q06187; -.
DR   ChEMBL; CHEMBL5251; -.
DR   DrugBank; DB09053; Ibrutinib.
DR   DrugBank; DB05204; XL418.
DR   GuidetoPHARMACOLOGY; 1948; -.
DR   iPTMnet; Q06187; -.
DR   PhosphoSitePlus; Q06187; -.
DR   BioMuta; BTK; -.
DR   DMDM; 547759; -.
DR   EPD; Q06187; -.
DR   MaxQB; Q06187; -.
DR   PaxDb; Q06187; -.
DR   PeptideAtlas; Q06187; -.
DR   PRIDE; Q06187; -.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000308731; ENSP00000308176; ENSG00000010671. [Q06187-1]
DR   Ensembl; ENST00000621635; ENSP00000483570; ENSG00000010671. [Q06187-2]
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   UCSC; uc004ehg.3; human. [Q06187-1]
DR   CTD; 695; -.
DR   DisGeNET; 695; -.
DR   GeneCards; BTK; -.
DR   GeneReviews; BTK; -.
DR   HGNC; HGNC:1133; BTK.
DR   HPA; CAB016689; -.
DR   HPA; HPA001198; -.
DR   HPA; HPA002028; -.
DR   MalaCards; BTK; -.
DR   MIM; 300300; gene.
DR   MIM; 300755; phenotype.
DR   MIM; 307200; phenotype.
DR   neXtProt; NX_Q06187; -.
DR   OpenTargets; ENSG00000010671; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   Orphanet; 47; X-linked agammaglobulinemia.
DR   PharmGKB; PA25454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233859; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; Q06187; -.
DR   KO; K07370; -.
DR   OMA; ELGTGQF; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; Q06187; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:Mal cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q06187; -.
DR   SIGNOR; Q06187; -.
DR   ChiTaRS; BTK; human.
DR   EvolutionaryTrace; Q06187; -.
DR   GeneWiki; Bruton%27s_tyrosine_kinase; -.
DR   GenomeRNAi; 695; -.
DR   PRO; PR:Q06187; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000010671; -.
DR   CleanEx; HS_BTK; -.
DR   ExpressionAtlas; Q06187; baseline and differential.
DR   Genevisible; Q06187; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:HGNC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0002344; P:B cell affinity maturation; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:HGNC.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0071226; P:cellular response to molecule of fungal origin; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:HGNC.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0001818; P:negative regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:CACAO.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; TAS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0001812; P:positive regulation of type I hypersensitivity; IEA:Ensembl.
DR   GO; GO:0001805; P:positive regulation of type III hypersensitivity; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:HGNC.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0002721; P:regulation of B cell cytokine production; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity;
KW   Alternative promoter usage; Apoptosis; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Immunity; Innate immunity; Kinase; Lipid-binding;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; SH2 domain; SH3 domain;
KW   Transcription; Transcription regulation; Transferase;
KW   Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.11}.
FT   CHAIN         2    659       Tyrosine-protein kinase BTK.
FT                                /FTId=PRO_0000088065.
FT   DOMAIN        3    133       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      214    274       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      281    377       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      402    655       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     135    171       Btk-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00432}.
FT   NP_BIND     408    416       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       12     24       Inositol-(1,3,4,5)-tetrakisphosphate 1-
FT                                binding.
FT   REGION      474    479       Inhibitor-binding.
FT   MOTIF       581    588       CAV1-binding.
FT   ACT_SITE    521    521       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       143    143       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       154    154       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       155    155       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   METAL       165    165       Zinc. {ECO:0000269|PubMed:10196129,
FT                                ECO:0000269|PubMed:9218782,
FT                                ECO:0000269|Ref.47}.
FT   BINDING      26     26       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      28     28       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      39     39       Inositol-(1,3,4,5)-tetrakisphosphate.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING      53     53       Inositol-(1,3,4,5)-tetrakisphosphate; via
FT                                carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10196129}.
FT   BINDING     430    430       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     445    445       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     461    461       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     477    477       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     538    538       Inhibitor. {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     539    539       Inhibitor; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   BINDING     542    542       Inhibitor; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:21280133,
FT                                ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.11}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000269|PubMed:16644721}.
FT   MOD_RES      40     40       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35991}.
FT   MOD_RES      55     55       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     115    115       Phosphoserine.
FT                                {ECO:0000269|PubMed:16644721}.
FT   MOD_RES     180    180       Phosphoserine; by PKC/PRKCB.
FT                                {ECO:0000269|PubMed:11598012}.
FT   MOD_RES     191    191       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     223    223       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12573241,
FT                                ECO:0000269|PubMed:17932028,
FT                                ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MOD_RES     344    344       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35991}.
FT   MOD_RES     361    361       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     551    551       Phosphotyrosine; by LYN and SYK.
FT                                {ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MOD_RES     604    604       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     617    617       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15375214}.
FT   MOD_RES     623    623       Phosphoserine.
FT                                {ECO:0000269|PubMed:15375214}.
FT   MOD_RES     659    659       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ       1      1       M -> MASWSIQQMVIGCPLCGRHCSGGEHTGELQKEEAM
FT                                (in isoform BTK-C). {ECO:0000305}.
FT                                /FTId=VSP_053838.
FT   VARIANT      11     11       L -> P (in XLA).
FT                                /FTId=VAR_006216.
FT   VARIANT      12     12       K -> R (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006217.
FT   VARIANT      14     14       S -> F (in XLA).
FT                                /FTId=VAR_006218.
FT   VARIANT      19     19       K -> E (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008291.
FT   VARIANT      25     25       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006219.
FT   VARIANT      27     27       K -> R (in XLA).
FT                                /FTId=VAR_008292.
FT   VARIANT      28     28       R -> C (in XLA; no effect on
FT                                phosphorylation of GTF2I).
FT                                /FTId=VAR_008293.
FT   VARIANT      28     28       R -> H (in XLA; moderate;
FT                                dbSNP:rs128620185).
FT                                {ECO:0000269|PubMed:7849721,
FT                                ECO:0000269|PubMed:8162018,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006220.
FT   VARIANT      28     28       R -> P (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006221.
FT   VARIANT      33     33       T -> P (in XLA; severe;
FT                                dbSNP:rs128620189).
FT                                {ECO:0000269|PubMed:7633429,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006222.
FT   VARIANT      39     39       Y -> S (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008960.
FT   VARIANT      40     40       Y -> C (in XLA).
FT                                /FTId=VAR_008294.
FT   VARIANT      40     40       Y -> N (in XLA).
FT                                /FTId=VAR_008295.
FT   VARIANT      61     61       I -> N (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008296.
FT   VARIANT      64     64       V -> D (in XLA).
FT                                /FTId=VAR_008297.
FT   VARIANT      64     64       V -> F (in XLA).
FT                                {ECO:0000269|PubMed:7849006}.
FT                                /FTId=VAR_006223.
FT   VARIANT      82     82       R -> K (in dbSNP:rs56035945).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041676.
FT   VARIANT     103    103       Q -> QSVFSSTR (in XLA).
FT                                /FTId=VAR_006224.
FT   VARIANT     113    113       V -> D (in XLA; dbSNP:rs128621190).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006225.
FT   VARIANT     115    115       S -> F (in XLA).
FT                                /FTId=VAR_008298.
FT   VARIANT     117    117       T -> P (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008299.
FT   VARIANT     127    127       Q -> H (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008300.
FT   VARIANT     154    154       C -> S (in XLA).
FT                                {ECO:0000269|PubMed:9280283}.
FT                                /FTId=VAR_008301.
FT   VARIANT     155    155       C -> G (in XLA).
FT                                /FTId=VAR_008302.
FT   VARIANT     155    155       C -> R (in XLA).
FT                                {ECO:0000269|PubMed:9280283,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008303.
FT   VARIANT     184    184       T -> P (in XLA).
FT                                /FTId=VAR_008304.
FT   VARIANT     190    190       P -> K (in a lung large cell carcinoma
FT                                sample; somatic mutation; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041677.
FT   VARIANT     260    280       Missing (in XLA; severe).
FT                                {ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006226.
FT   VARIANT     288    288       R -> Q (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008305.
FT   VARIANT     288    288       R -> W (in XLA; dbSNP:rs128621194).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:8162018,
FT                                ECO:0000269|PubMed:8162056,
FT                                ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006227.
FT   VARIANT     295    295       L -> P (in XLA).
FT                                {ECO:0000269|PubMed:8723128,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006228.
FT   VARIANT     302    302       G -> E (in XLA).
FT                                {ECO:0000269|PubMed:7627183,
FT                                ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006230.
FT   VARIANT     302    302       G -> R (in XLA).
FT                                /FTId=VAR_008306.
FT   VARIANT     302    302       Missing (in XLA).
FT                                {ECO:0000269|PubMed:7633429}.
FT                                /FTId=VAR_006229.
FT   VARIANT     307    307       R -> G (in XLA; loss of activity;
FT                                dbSNP:rs128621195).
FT                                {ECO:0000269|PubMed:8162056}.
FT                                /FTId=VAR_006231.
FT   VARIANT     307    307       R -> T (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008307.
FT   VARIANT     308    308       D -> E (in XLA).
FT                                /FTId=VAR_008308.
FT   VARIANT     319    319       V -> A (in XLA; moderate).
FT                                /FTId=VAR_008309.
FT   VARIANT     334    334       Y -> S (in XLA; dbSNP:rs128621196).
FT                                {ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006232.
FT   VARIANT     358    358       L -> F (in XLA).
FT                                {ECO:0000269|PubMed:7897635}.
FT                                /FTId=VAR_006233.
FT   VARIANT     361    361       Y -> C (in XLA; mild; dbSNP:rs28935478).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006234.
FT   VARIANT     362    362       H -> Q (in XLA).
FT                                /FTId=VAR_006235.
FT   VARIANT     364    364       H -> P (in XLA).
FT                                /FTId=VAR_006236.
FT   VARIANT     365    365       N -> Y (in XLA).
FT                                /FTId=VAR_006237.
FT   VARIANT     366    366       S -> F (in XLA).
FT                                /FTId=VAR_008310.
FT   VARIANT     369    369       L -> F (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008311.
FT   VARIANT     370    370       I -> M (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006238.
FT   VARIANT     372    372       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008312.
FT   VARIANT     408    408       L -> P (in XLA; moderate;
FT                                dbSNP:rs128621198).
FT                                {ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006239.
FT   VARIANT     414    414       G -> R (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008313.
FT   VARIANT     418    418       Y -> H (in XLA; dbSNP:rs144079566).
FT                                /FTId=VAR_006240.
FT   VARIANT     429    429       I -> N (in XLA).
FT                                {ECO:0000269|PubMed:8634718}.
FT                                /FTId=VAR_006241.
FT   VARIANT     430    430       K -> E (in XLA; loss of phosphorylation
FT                                of GTF2I; dbSNP:rs128620184).
FT                                {ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006242.
FT   VARIANT     430    430       K -> R (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008314.
FT   VARIANT     445    445       E -> D (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008315.
FT   VARIANT     462    462       G -> D (in XLA).
FT                                /FTId=VAR_008316.
FT   VARIANT     462    462       G -> V (in XLA).
FT                                /FTId=VAR_008317.
FT   VARIANT     476    476       Y -> D (in XLA).
FT                                {ECO:0000269|PubMed:7627183}.
FT                                /FTId=VAR_006243.
FT   VARIANT     477    477       M -> R (in XLA).
FT                                {ECO:0000269|PubMed:8634718}.
FT                                /FTId=VAR_006244.
FT   VARIANT     481    481       C -> S (found in patients with chronic
FT                                lymphocytic leukemia; unknown
FT                                pathological significance; results in
FT                                resistance to ibrutinib therapy; results
FT                                in a protein that is reversibly inhibited
FT                                by ibrutinib; disrupts the covalent
FT                                binding between the enzyme and
FT                                ibrutinib). {ECO:0000269|PubMed:24869597,
FT                                ECO:0000269|PubMed:24869598,
FT                                ECO:0000269|PubMed:25189416}.
FT                                /FTId=VAR_074309.
FT   VARIANT     502    502       C -> F (in XLA).
FT                                /FTId=VAR_006245.
FT   VARIANT     502    502       C -> W (in XLA; dbSNP:rs41310709).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006246.
FT   VARIANT     506    506       C -> R (in XLA; dbSNP:rs128621200).
FT                                {ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006247.
FT   VARIANT     506    506       C -> Y (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006248.
FT   VARIANT     508    508       A -> D (in XLA).
FT                                /FTId=VAR_008318.
FT   VARIANT     509    509       M -> I (in XLA).
FT                                /FTId=VAR_008319.
FT   VARIANT     509    509       M -> V (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006249.
FT   VARIANT     512    512       L -> P (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008961.
FT   VARIANT     512    512       L -> Q (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008962.
FT   VARIANT     518    518       L -> R (in XLA).
FT                                /FTId=VAR_008320.
FT   VARIANT     520    520       R -> Q (in XLA; severe; prevents
FT                                activation due to absence of contact
FT                                between the catalytic loop and the
FT                                regulatory phosphorylated residue;
FT                                dbSNP:rs128621202).
FT                                {ECO:0000269|PubMed:7633429,
FT                                ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006251.
FT   VARIANT     521    521       D -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008321.
FT   VARIANT     521    521       D -> H (in XLA; severe).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006252.
FT   VARIANT     521    521       D -> N (in XLA; severe).
FT                                /FTId=VAR_006253.
FT   VARIANT     523    523       A -> E (in XLA).
FT                                /FTId=VAR_008322.
FT   VARIANT     525    525       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008323.
FT   VARIANT     525    525       R -> P (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006254.
FT   VARIANT     525    525       R -> Q (in XLA; severe; disturbs ATP-
FT                                binding; dbSNP:rs128620183).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006255.
FT   VARIANT     526    526       N -> K (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006256.
FT   VARIANT     535    535       V -> F (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008324.
FT   VARIANT     542    542       L -> P (in XLA; growth hormone
FT                                deficiency; dbSNP:rs128621203).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006257.
FT   VARIANT     544    544       R -> G (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008963.
FT   VARIANT     544    544       R -> K (in XLA).
FT                                {ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006258.
FT   VARIANT     559    559       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008325.
FT   VARIANT     562    562       R -> P (in XLA; dbSNP:rs28935176).
FT                                {ECO:0000269|PubMed:10678660,
FT                                ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006259.
FT   VARIANT     562    562       R -> W (in XLA; dbSNP:rs128621204).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006260.
FT   VARIANT     563    563       W -> L (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008326.
FT   VARIANT     567    567       E -> K (in XLA; severe).
FT                                {ECO:0000269|PubMed:7633420}.
FT                                /FTId=VAR_006261.
FT   VARIANT     578    578       S -> Y (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008964.
FT   VARIANT     581    581       W -> R (in XLA; dbSNP:rs128621205).
FT                                /FTId=VAR_006262.
FT   VARIANT     582    582       A -> V (in XLA).
FT                                {ECO:0000269|PubMed:7711734,
FT                                ECO:0000269|PubMed:7809124}.
FT                                /FTId=VAR_006263.
FT   VARIANT     583    583       F -> S (in XLA).
FT                                /FTId=VAR_008327.
FT   VARIANT     587    587       M -> L (in XLA; mild).
FT                                {ECO:0000269|PubMed:7633420}.
FT                                /FTId=VAR_006264.
FT   VARIANT     589    589       E -> D (in XLA).
FT                                /FTId=VAR_008328.
FT   VARIANT     589    589       E -> G (in XLA; moderate; interferes with
FT                                substrate binding; dbSNP:rs128621206).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006265.
FT   VARIANT     589    589       E -> K (in XLA).
FT                                {ECO:0000269|PubMed:10612838}.
FT                                /FTId=VAR_008965.
FT   VARIANT     592    592       S -> P (in XLA).
FT                                {ECO:0000269|PubMed:8834236}.
FT                                /FTId=VAR_006267.
FT   VARIANT     594    594       G -> E (in XLA; mild; interferes with
FT                                substrate binding).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006268.
FT   VARIANT     594    594       G -> R (in XLA).
FT                                {ECO:0000269|PubMed:7711734}.
FT                                /FTId=VAR_006269.
FT   VARIANT     598    598       Y -> C (in XLA).
FT                                /FTId=VAR_006270.
FT   VARIANT     607    607       A -> D (in XLA; mild; dbSNP:rs128621208).
FT                                {ECO:0000269|PubMed:8162056}.
FT                                /FTId=VAR_006271.
FT   VARIANT     613    613       G -> D (in XLA; mild; interferes with
FT                                substrate binding and/or domain
FT                                interactions; dbSNP:rs128621209).
FT                                {ECO:0000269|PubMed:7809124,
FT                                ECO:0000269|PubMed:7849721}.
FT                                /FTId=VAR_006272.
FT   VARIANT     619    619       P -> A (in XLA).
FT                                /FTId=VAR_008330.
FT   VARIANT     619    619       P -> S (in XLA).
FT                                /FTId=VAR_006273.
FT   VARIANT     619    619       P -> T (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008331.
FT   VARIANT     622    622       A -> P (in XLA).
FT                                {ECO:0000269|PubMed:9545398}.
FT                                /FTId=VAR_008332.
FT   VARIANT     626    626       V -> G (in XLA).
FT                                {ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_008333.
FT   VARIANT     630    630       M -> I (polymorphism, 35%).
FT                                /FTId=VAR_006274.
FT   VARIANT     630    630       M -> K (in XLA; dbSNP:rs128621210).
FT                                {ECO:0000269|PubMed:7849697,
FT                                ECO:0000269|PubMed:7880320}.
FT                                /FTId=VAR_006275.
FT   VARIANT     630    630       M -> T (in XLA).
FT                                /FTId=VAR_008334.
FT   VARIANT     633    633       C -> Y (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006276.
FT   VARIANT     641    641       R -> C (in XLA).
FT                                {ECO:0000269|PubMed:7633429}.
FT                                /FTId=VAR_006277.
FT   VARIANT     641    641       R -> H (in XLA; severe).
FT                                {ECO:0000269|PubMed:7633420,
FT                                ECO:0000269|PubMed:9445504}.
FT                                /FTId=VAR_006278.
FT   VARIANT     644    644       F -> L (in XLA).
FT                                /FTId=VAR_008335.
FT   VARIANT     644    644       F -> S (in XLA).
FT                                {ECO:0000269|PubMed:8695804}.
FT                                /FTId=VAR_006279.
FT   VARIANT     647    647       L -> P (in XLA).
FT                                /FTId=VAR_006280.
FT   VARIANT     652    652       L -> P (in XLA; dbSNP:rs128622212).
FT                                {ECO:0000269|PubMed:7849697}.
FT                                /FTId=VAR_006281.
FT   MUTAGEN      41     41       E->K: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     189    189       P->A: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     223    223       Y->F: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:8630736,
FT                                ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     251    252       WW->LL: Large decrease in binding by
FT                                SH3BP5. {ECO:0000269|PubMed:9571151}.
FT   MUTAGEN     251    251       W->L: No effect on phosphorylation of
FT                                GTF2I. {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     307    307       R->K: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     551    551       Y->F: Loss of phosphorylation of GTF2I.
FT                                {ECO:0000269|PubMed:9012831}.
FT   MUTAGEN     617    617       Y->E: Defective in mediating calcium
FT                                response. {ECO:0000269|PubMed:15375214}.
FT   CONFLICT    253    253       R -> K (in Ref. 7; BAG37008).
FT                                {ECO:0000305}.
FT   STRAND        6     13       {ECO:0000244|PDB:1BTK}.
FT   STRAND       18     20       {ECO:0000244|PDB:2Z0P}.
FT   STRAND       25     32       {ECO:0000244|PDB:1BTK}.
FT   STRAND       34     43       {ECO:0000244|PDB:1BTK}.
FT   TURN         44     47       {ECO:0000244|PDB:1BTK}.
FT   STRAND       48     57       {ECO:0000244|PDB:1BTK}.
FT   HELIX        58     60       {ECO:0000244|PDB:1BTK}.
FT   STRAND       61     66       {ECO:0000244|PDB:1BTK}.
FT   HELIX        75     77       {ECO:0000244|PDB:1BTK}.
FT   HELIX        93     96       {ECO:0000244|PDB:1BTK}.
FT   STRAND      100    106       {ECO:0000244|PDB:1BTK}.
FT   STRAND      111    116       {ECO:0000244|PDB:1BTK}.
FT   HELIX       118    132       {ECO:0000244|PDB:1BTK}.
FT   STRAND      140    142       {ECO:0000244|PDB:1BTK}.
FT   STRAND      149    152       {ECO:0000244|PDB:2Z0P}.
FT   TURN        153    155       {ECO:0000244|PDB:1BTK}.
FT   STRAND      165    167       {ECO:0000244|PDB:1BTK}.
FT   TURN        212    215       {ECO:0000244|PDB:1AWX}.
FT   STRAND      218    223       {ECO:0000244|PDB:1AWW}.
FT   STRAND      228    232       {ECO:0000244|PDB:1AWW}.
FT   STRAND      240    242       {ECO:0000244|PDB:1AWW}.
FT   STRAND      248    252       {ECO:0000244|PDB:1AWW}.
FT   TURN        257    259       {ECO:0000244|PDB:1QLY}.
FT   STRAND      261    265       {ECO:0000244|PDB:1AWX}.
FT   TURN        266    268       {ECO:0000244|PDB:1AWW}.
FT   STRAND      279    282       {ECO:0000244|PDB:2GE9}.
FT   HELIX       288    298       {ECO:0000244|PDB:2GE9}.
FT   STRAND      303    308       {ECO:0000244|PDB:2GE9}.
FT   STRAND      310    312       {ECO:0000244|PDB:2GE9}.
FT   STRAND      315    326       {ECO:0000244|PDB:2GE9}.
FT   STRAND      330    335       {ECO:0000244|PDB:2GE9}.
FT   STRAND      337    339       {ECO:0000244|PDB:2GE9}.
FT   TURN        340    342       {ECO:0000244|PDB:2GE9}.
FT   STRAND      343    347       {ECO:0000244|PDB:2GE9}.
FT   STRAND      350    354       {ECO:0000244|PDB:2GE9}.
FT   HELIX       355    363       {ECO:0000244|PDB:2GE9}.
FT   STRAND      373    376       {ECO:0000244|PDB:2GE9}.
FT   HELIX       393    395       {ECO:0000244|PDB:3PJ2}.
FT   HELIX       399    401       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      402    411       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      414    421       {ECO:0000244|PDB:4RFZ}.
FT   TURN        422    424       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      425    431       {ECO:0000244|PDB:4RFZ}.
FT   TURN        434    436       {ECO:0000244|PDB:5FBO}.
FT   HELIX       439    450       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      460    464       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      466    469       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      471    475       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       482    487       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       489    491       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       495    514       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       524    526       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      527    529       {ECO:0000244|PDB:4RFZ}.
FT   STRAND      535    537       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       542    545       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       549    552       {ECO:0000244|PDB:4RFZ}.
FT   TURN        554    556       {ECO:0000244|PDB:3PIX}.
FT   HELIX       561    563       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       566    571       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       576    591       {ECO:0000244|PDB:4RFZ}.
FT   TURN        592    594       {ECO:0000244|PDB:5U9D}.
FT   TURN        597    600       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       603    611       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       624    632       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       638    640       {ECO:0000244|PDB:4RFZ}.
FT   HELIX       644    657       {ECO:0000244|PDB:4RFZ}.
SQ   SEQUENCE   659 AA;  76281 MW;  DF06B5D1FEC257CC CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAEKH LFSTIPELIN
     YHQHNSAGLI SRLKYPVSQQ NKNAPSTAGL GYGSWEIDPK DLTFLKELGT GQFGVVKYGK
     WRGQYDVAIK MIKEGSMSED EFIEEAKVMM NLSHEKLVQL YGVCTKQRPI FIITEYMANG
     CLLNYLREMR HRFQTQQLLE MCKDVCEAME YLESKQFLHR DLAARNCLVN DQGVVKVSDF
     GLSRYVLDDE YTSSVGSKFP VRWSPPEVLM YSKFSSKSDI WAFGVLMWEI YSLGKMPYER
     FTNSETAEHI AQGLRLYRPH LASEKVYTIM YSCWHEKADE RPTFKILLSN ILDVMDEES
//
